摘要
目的探讨重组组织型纤溶酶原激活物静脉溶栓联合介入治疗在急性缺血性脑卒中患者中的应用效果。方法选取2018年1月至2021年5月大连大学附属中山医院收治的100例急性缺血性脑卒中患者作为研究对象,按照随机数字表法分为对照组(50例)与观察组(50例)。对照组患者接受重组组织型纤溶酶原激活物静脉溶栓治疗,观察组患者接受重组组织型纤溶酶原激活物静脉溶栓联合介入治疗,比较两组的临床疗效、治疗前后功能障碍严重程度[改良Rankin量表(MRS)]、生活自理能力[改良Barthel指数(MBI)]、脑部血流动力学指标水平及不良反应发生率。结果观察组的治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗前,两组的MRS评分、MBI评分及脑部血流速度、最小血流量、动态阻抗等指标比较,差异无统计学意义(P>0.05);观察组治疗后的MRS评分低于对照组,MBI评分及脑部血流速度、最小血流量、动态阻抗等指标水平高于对照组,差异有统计学意义(P<0.05);两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论急性缺血性脑卒中患者接受重组组织型纤溶酶原激活物静脉溶栓联合介入治疗的效果较好,可显著改善其功能障碍及脑部血流动力学指标,促进生活自理能力的恢复,且不良反应较少,具有较高的临床推广价值。
Objective To investigate the application effect of intravenous thrombolysis with recombinant tissue-type plasminogen activator combined with interventional therapy in patients with acute ischemic stroke.Methods A total of 100 patients with acute ischemic stroke in Zhongshan Hospital Affiliated to Dalian University from January 2018 to may 2021 were selected as the research object.They were divided into the control group(50 cases)and the observation group(50 cases)according to the random number table method.The patients in the control group received intravenous thrombolysis with recombinant tissue-type plasminogen activator,the patients in the observation group received intravenous thrombolysis with recombinant tissue-type plasminogen activator combined with interventional therapy.The clinical efficacy,the severity of dysfunction(modified Rankin scale[MRS]),the ability of self-care(modified Barthel index[MBI]),the level of cerebral hemodynamics before and after treatment and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the MRS score,MBI score,cerebral blood flow velocity,minimum blood flow and dynamic impedance between the two groups(P>0.05).After treatment,the MRS score of the observation group was lower than that of the control group,the MBI score,cerebral blood flow velocity,minimum blood flow and dynamic impedance in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Intravenous thrombolytic therapy with recombinant tissue-type plasminogen activator combined with interventional therapy has a good effect on patients with acute ischemic stroke,which can significantly improve their functional disorders and cerebral hemodynamic indexes,and promote the recovery of self-care ability,with fewer adverse reactions,and has a higher clinical promotion value.
作者
孙涌津
朴翔宇
SUN Yongjin;PIAO Xiangyu(Department of Neurology,Zhongshan Hospital Affiliated to Dalian University,Liaoning Province,Dalian116001,China)
出处
《中国当代医药》
CAS
2022年第22期88-91,共4页
China Modern Medicine
基金
辽宁省大连市医学科学研究计划项目(1811105)。
关键词
急性缺血性脑卒中
重组组织型纤溶酶原激活物
静脉溶栓
介入治疗
Acute ischemic stroke
Recombinant tissue-type plasminogen activator
Intravenous thrombolysis
Interventional therapy
